Annals of Surgical Oncology

, Volume 20, Issue 4, pp 1063–1067 | Cite as

Right Hemicolectomy for Mucinous Adenocarcinoma of the Appendix: Just Right or Too Much?

Regional Cancer Therapies

Abstract

Background

The surgical management of mucinous adenocarcinoma of the appendix (MA) is controversial, given its infrequent nodal metastases and its propensity for peritoneal dissemination compared to nonmucinous adenocarcinoma. We sought to identify the appropriateness of a right hemicolectomy (RH) for MA in staging and treatment of these tumors.

Methods

We queried all patients with MA captured in the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2007. Demographics, and tumor and therapy characteristics were extracted. Overall and disease-specific survival was compared by Cox regression analyses.

Results

Of 2,101 patients with MA, the median age was 59 (range 49–72) years; 55 % were women (n = 1,151). Tumor, node, metastasis staging revealed that tumors were frequently T3 (33 %) or T4 (46 %), N0 (80 %), and M1 (46 %). Fifty-one percent (n = 666) of patients underwent an appendectomy. In patients with complete staging information who underwent RH, nodal metastases were less frequent than the nonmucinous adenocarcinoma group (odds ratio 0.63, p = 0.003). Well-differentiated tumors had a low likelihood of nodal metastases (6 % T1, 0 % T2, 7 % T3, 22 % T4). Adjusted survival for patients undergoing appendectomy was similar to those undergoing a RH (hazard ratio 0.93, p = 0.52). Median survival for both groups was similar with positive nodes (28 [appendectomy] vs. 26 months [RH], p = 0.26) or metastatic disease (52 [appendectomy] vs. 43 months [RH], p = 0.28).

Conclusions

There does not appear to be a therapeutic benefit to a RH in the setting of known node-positive or metastatic disease. Benefits of a staging operation can be individualized on the basis of the probability of nodal metastases, which is lower than nonmucinous tumors.

References

  1. 1.
    Turaga KK, Pappas SG, Gamblin TC. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol. 2012;19:1379–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Hesketh KT. The management of primary adenocarcinoma of the vermiform appendix. Gut. 1963;4:158–68.PubMedCrossRefGoogle Scholar
  3. 3.
    Gonzalez-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg. 2004;91:304–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Foster JM, Gupta PK, Carreau JH, et al. Right hemicolectomy is not routinely indicated in pseudomyxoma peritonei. Am Surg. 2012;78:171–7.PubMedGoogle Scholar
  5. 5.
    Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American college of surgeons oncology group Z0011 randomized trial. Ann Surg. 2010;252:426–32.PubMedGoogle Scholar
  6. 6.
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.PubMedCrossRefGoogle Scholar
  7. 7.
    Titu LV, Tweedle E, Rooney PS. High tie of the inferior mesenteric artery in curative surgery for left colonic and rectal cancers: a systematic review. Dig Surg. 2008;25:148–57.PubMedCrossRefGoogle Scholar
  8. 8.
    Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693–701.PubMedCrossRefGoogle Scholar
  9. 9.
    van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Kanemitsu Y, Hirai T, Komori K, et al. Survival benefit of high ligation of the inferior mesenteric artery in sigmoid colon or rectal cancer surgery. Br J Surg. 2006;93:609–15.PubMedCrossRefGoogle Scholar
  11. 11.
    National Cancer Institute. Surveillance epidemiology and end results, 2010. http://seer.cancer.gov/about/. Accessed 21 Jan 2011.
  12. 12.
    Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Levine EA, Stewart JHT, Russell GB, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204:943–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Piso P, Glockzin G, von Breitenbuch P, et al. Patient selection for a curative approach to carcinomatosis. Cancer J. 2009;15:236–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol. 2007;14:2289–99.PubMedCrossRefGoogle Scholar
  16. 16.
    Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.PubMedCrossRefGoogle Scholar
  17. 17.
    Panarelli NC, Yantiss RK. Mucinous neoplasms of the appendix and peritoneum. Arch Pathol Lab Med. 2011;135:1261–8.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Kiran K. Turaga
    • 1
  • Sam Pappas
    • 1
  • T. Clark Gamblin
    • 1
  1. 1.Division of Surgical OncologyMedical College of WisconsinMilwaukeeUSA

Personalised recommendations